The Bronchiolitis drugs in development market research report provides comprehensive information on the therapeutics under development for Bronchiolitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Bronchiolitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Bronchiolitis and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Bronchiolitis by 13 companies/universities/institutes. The top development phase for Bronchiolitis is phase iii with five drugs in that stage. The Bronchiolitis pipeline has 13 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Bronchiolitis pipeline products market are: Boehringer Ingelheim International, SolAeroMed and F. Hoffmann-La Roche.
The key targets in the Bronchiolitis pipeline products market include Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2), Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2), and Vascular Endothelial Growth Factor Receptor 3 (Fms Like Tyrosine Kinase 4 or Tyrosine Protein Kinase Receptor FLT4 or VEGFR3 or FLT4 or EC 2.7.10.1).
The key mechanisms of action in the Bronchiolitis pipeline product include Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16) Inhibitor with one drug in Phase III. The Bronchiolitis pipeline products include seven routes of administration with the top ROA being Inhalational and two key molecule types in the Bronchiolitis pipeline products market including Small Molecule, and Recombinant Protein.
Bronchiolitis overview
Bronchiolitis is inflammation of the small airways in the lungs. It is the most common lower respiratory tract infection in pediatric patients between 1 month and 2 years of age. It is usually caused by the respiratory syncytial virus (RSV) and is characterized by inflammation, edema, and necrosis of the bronchiole’s epithelium. It is transmitted by air droplets. symptoms of bronchiolitis include fever, cough, dyspnea, and Nasal discharge.
For a complete picture of Bronchiolitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
